Latest Clinical Lymphoma & Myeloma Stories

2011-05-10 06:30:00

CALGARY, May 10 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, U.S. National Cancer Institute (NCI), which is part of the National Institutes of Health, has agreed to sponsor a Phase I study of REOLYSIN(®) alone in patients with relapsed multiple myeloma. The NCI is sponsoring the trial under its Clinical Trials Agreement with...

2011-04-12 10:40:00

NEW YORK, April 12, 2011 /PRNewswire-USNewswire/ -- The Bone and Cancer Foundation (BCF) provides information for cancer patients who have bone related complications including metastasis and cancer treatment induced bone loss. BCF patient publications cover very timely topics including Vitamin D and new treatment options, and are the only publications available that deal specifically with bone metastasis and cancer treatment induced bone loss. The following patient publications have been...

2010-12-06 14:01:56

Results with Estybon (ON 01910.Na) in Patients with myelodysplastic syndromes; ON 013105 cyclin D1 inhibitor active in models of mantle cell lymphoma NEWTOWN, PA and PRINCETON, NJ Dec. 3, 2010 / PRNewswire-FirstCall / Onconova Therapeutics announces its late-stage anticancer agent, Estybon® (ON 01910.Na), will be featured in three presentations at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, FL, December 4-7, 2010. Principal investigators at four...

2010-12-01 09:00:00

NEW YORK, Dec. 1, 2010 /PRNewswire/ -- Signal Genetics, the parent company of Myeloma Health, a privately held predictive genetic testing company focused on oncology, today announced the launch of their revolutionary molecular test for individuals diagnosed with multiple myeloma, MyPRS(TM). The official launch of MyPRS(TM) will take place at the 52nd Annual American Society of Hematology (ASH) Meeting and Exposition in Orlando, Florida on December 4th. As part of the product launch the...

2010-12-01 07:00:00

WHITE PLAINS, N.Y., Dec. 1, 2010 /PRNewswire/ -- Researchers from around the world will present their findings in blood cancer research at the annual American Society of Hematology (ASH) conference in Orlando December 4-7, 2010. Throughout the ASH conference, LLS Vice President of Research Communications Deborah Banker, Ph.D., will be available to comment on any research news to emerge from the meeting. To arrange interviews in advance or during the conference, please contact Andrea...

2010-10-26 12:00:00

NEW YORK, Oct. 26 /PRNewswire/ -- Signal Genetics, the parent company of Myeloma Health, a privately held predictive genetic testing company focused on oncology, today announced the formation of their Scientific Advisory Board. They include: Kenneth Anderson, M.D. Director, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute Kraft Family Professor of Medicine, Harvard Medical School Dr. Anderson of Dana-Farber Cancer Institute and Harvard Medical School holds the title of...

Word of the Day
  • A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
  • A gentle breeze; a waft; a breath.
  • Any rumor that engages general attention.
  • A cant or whining mode of speaking, especially in preaching or praying; the chant or recitative characteristic of the old Presbyterians in Scotland.
  • To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
  • To breathe in or as in sleep.
  • To utter in a whining or monotonous tone.
According to the OED, from the 16th century, this word is 'almost exclusively Scots and northern dialect until adopted in general literary use in the 19th.'